| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 12/24/2008 | CN100445252C Active compound bulbophyllum phenanthrene dimer B and its use |
| 12/24/2008 | CN100444891C Medicine for treating continousely tuberculosis after failure of vertebral-body concretion operation |
| 12/24/2008 | CN100444869C External-use plaster for treating hyperosteogeny and preparing method |
| 12/24/2008 | CN100444867C Utilization of extracts from iris plants, cimicifuga racemosa and tectorigenin as estrofen-like organ-selective medicament without uteroetropic effects |
| 12/24/2008 | CN100444866C Synergistic medicinal composition |
| 12/24/2008 | CN100444865C Synergistic medicinal composition containing dicyclic alcohol |
| 12/24/2008 | CN100444861C A compound Chinese medicine for treating bone fracture quickly |
| 12/24/2008 | CN100444857C Medicine for auxiliary treating hepatitis |
| 12/24/2008 | CN100444854C Ointment for treating phlebitis and method for preparing same |
| 12/24/2008 | CN100444851C Use of chrysanthemum total flavone for preparing drugs for treating arythmia |
| 12/24/2008 | CN100444848C Pharmaceutical composition for improved administration of HIV gp41-derived peptides,And its use in therapy |
| 12/24/2008 | CN100444847C Micronize diosmin and hesperidine composition suppository |
| 12/24/2008 | CN100444846C Dispersion tablet contg. Gynostemma petaphylla total glucosides, and its prepn. method |
| 12/24/2008 | CN100444845C Biologic adhesion preparation of total saponin of notoginseng for gastrointestinal tract |
| 12/24/2008 | CN100444844C Composition for repairing and promoting regeneration of gastrointestinal tract mucous tissue and its preparation method thereof |
| 12/24/2008 | CN100444843C Sustained release oral preparations of fasudil hydrochloride |
| 12/24/2008 | CN100444842C Use of N-aryl heterocyclics |
| 12/24/2008 | CN100444841C Externally used loratadine formulation |
| 12/24/2008 | CN100444840C Method for reducing amyloid deposition, amyloid neurotoxicity and microgliosis |
| 12/24/2008 | CN100444839C Treatment of chemokine mediated diseases |
| 12/24/2008 | CN100444838C Use of inhibitors for treatment of disorders related to RTK hyperfunction |
| 12/24/2008 | CN100444837C Novel herbal chemical composition for treatment of cancer |
| 12/24/2008 | CN100444836C Injecting composition containing Sodium Danshensu |
| 12/24/2008 | CN100444833C Oral dosage form for controlled drug release |
| 12/24/2008 | CN100444831C Compound dripping pills of licorice and its preparing process |
| 12/24/2008 | CN100444830C Multiparticulate modified release composition |
| 12/24/2008 | CA2721135A1 A zwitterion solution for low-volume therapeutic delivery |
| 12/24/2008 | CA2721134A1 A baclofen solution for low-volume therapeutic delivery |
| 12/24/2008 | CA2698172A1 Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties |
| 12/24/2008 | CA2693627A1 Short acting phenylalkylamine calcium channel blockers and uses thereof |
| 12/24/2008 | CA2693062A1 Methods and compositions for stimulating neurogenesis and inhibiting neuronal degeneration using isothiazolopyrimidinones |
| 12/24/2008 | CA2692249A1 Pyrazolone derivative and pde inhibitor containing the same as active ingredient |
| 12/24/2008 | CA2692248A1 Pyridazinone derivative and pde inhibitor containing the same as active ingredient |
| 12/24/2008 | CA2692178A1 Substituted oxazolidinones and use thereof |
| 12/24/2008 | CA2692172A1 Substituted oxazolidinones and the use thereof |
| 12/24/2008 | CA2692170A1 Azolylmethylidenehydrazine derivative and use thereof |
| 12/24/2008 | CA2692166A1 Substituted (oxazolidinon-5-yl-methyl)-2-thiophene-carboxamides and use thereof in the field of blood coagulation |
| 12/24/2008 | CA2692135A1 Boron-containing small molecules |
| 12/24/2008 | CA2692099A1 Sirtuin modulating imidazothiazole compounds |
| 12/24/2008 | CA2692075A1 Pharmaceutical composition comprising a trihydroxy-chromen-one derivative |
| 12/24/2008 | CA2692072A1 Methods and agents for inhibiting tumor growth |
| 12/24/2008 | CA2692039A1 Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating crf receptor signaling |
| 12/24/2008 | CA2692028A1 Azapeptide derivatives |
| 12/24/2008 | CA2691991A1 Treatment of pulmonary hypertension with carbonic anhydrase inhibitors |
| 12/24/2008 | CA2691776A1 Substituted imidazoheterocycles |
| 12/24/2008 | CA2691733A1 Sirtuin modulating compounds |
| 12/24/2008 | CA2691691A1 Compositions and methods of treating chronic kidney disease |
| 12/24/2008 | CA2691654A1 Treatment of meconium aspiration syndrome with estrogens |
| 12/24/2008 | CA2691648A1 Cinnoline compounds for use in the treatment of schizophrenia |
| 12/24/2008 | CA2691522A1 Phthalimide derivatives that influence cellular vesicular systems, pharmaceutical compositions, and use thereof |
| 12/24/2008 | CA2691417A1 Heterocyclic compounds and use thereof as erk inhibitors |
| 12/24/2008 | CA2691379A1 Substituted n-aryl pyridinones |
| 12/24/2008 | CA2691309A1 Tricyclic inhibitors of hydroxysteroid dehydrogenases |
| 12/24/2008 | CA2691251A1 Preventive/remedy for cancer |
| 12/24/2008 | CA2691237A1 Compounds and uses thereof-848 |
| 12/24/2008 | CA2691227A1 Activators and therapeutic applications thereof |
| 12/24/2008 | CA2691223A1 6-(pyrrolopyridinyl) pyrimidin-2-ylamine derivatives and the use thereof for the treatment of cancer and aids |
| 12/24/2008 | CA2691208A1 Combination therapy for depression |
| 12/24/2008 | CA2691150A1 Spirocycles as inhibitors of 11-beta hydroxyl steroid dehydrogenase type 1 |
| 12/24/2008 | CA2691132A1 Materials and methods for treatment and diagnosis of disorders associated with oxidative stress |
| 12/24/2008 | CA2691100A1 Protein kinase inhibitors and methods for using thereof |
| 12/24/2008 | CA2691071A1 Neurosteroid compounds |
| 12/24/2008 | CA2691056A1 Bromo-phenyl substituted thiazolyl dihydropyrimidines for treating and preventing hepatitis b infections |
| 12/24/2008 | CA2691019A1 Indazolamide derivatives |
| 12/24/2008 | CA2690945A1 Composition for transdermal or transmucosal administration |
| 12/24/2008 | CA2690762A1 .alpha.-chloro and .alpha.-bromo phosphonate analogs of lysophosphatidic acid and methods of making and using thereof |
| 12/24/2008 | CA2690749A1 Oncogenic all-1 fusion proteins for targeting drosha-mediated microrna processing |
| 12/24/2008 | CA2690746A1 Compounds for treatment |
| 12/24/2008 | CA2690557A1 Imidazopyrazines as protein kinase inhibitors |
| 12/24/2008 | CA2690545A1 Substituted bicyclic heteroaryl compounds and their use |
| 12/24/2008 | CA2690527A1 Substituted furopyrimidines and use thereof |
| 12/24/2008 | CA2690449A1 Synergistic treatment of cells that express epha2 and erbb2 |
| 12/24/2008 | CA2690436A1 Amine salts of a crth2 antagonist |
| 12/24/2008 | CA2690410A1 Kinase inhibitors, compositions thereof, and methods of use therewith |
| 12/24/2008 | CA2690401A1 Device and method for restoration of the condition of blood |
| 12/24/2008 | CA2690379A1 Substituted piperazines |
| 12/24/2008 | CA2690357A1 Bifunctional synthetic molecules |
| 12/24/2008 | CA2690271A1 Chlamydia antigens |
| 12/24/2008 | CA2690249A1 Spiro [piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis |
| 12/24/2008 | CA2690172A1 Particulates of a crth2 antagonist |
| 12/24/2008 | CA2690141A1 Inhibitors of janus kinases |
| 12/24/2008 | CA2690079A1 Sulfonyl-quinoline derivatives |
| 12/24/2008 | CA2689663A1 Salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
| 12/24/2008 | CA2689525A1 Cetp inhibitors derived from benzoxazole arylamides |
| 12/24/2008 | CA2689523A1 Cetp inhibitors derived from benzoxazole arylamides |
| 12/24/2008 | CA2689467A1 Pharmaceutical solid preparation comprising benzazepines and production method thereof |
| 12/24/2008 | CA2689393A1 Alkynylpyrimidines as tie2 kinase inhibitors |
| 12/24/2008 | CA2689208A1 Derivatives of 4-(n-azacycloalkyl) anilides as potassium channel modulators |
| 12/24/2008 | CA2689158A1 Metabolites of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
| 12/24/2008 | CA2688487A1 Compounds and compositions as itpkb inhibitors |
| 12/24/2008 | CA2688441A1 Substituted aromatic heterocyclic compounds as fungicides |
| 12/24/2008 | CA2687909A1 Indolin-2-ones and aza-indolin-2-ones |
| 12/24/2008 | CA2687258A1 Arylamide pyrimidone derivatives |
| 12/24/2008 | CA2687255A1 Heteroarylamide pyrimidone derivatives |
| 12/24/2008 | CA2687217A1 Antibiotic compounds |
| 12/24/2008 | CA2687156A1 Arylamide pyrimidone compounds |
| 12/24/2008 | CA2687151A1 Heteroarylamide pyrimidone compounds |
| 12/23/2008 | US7468462 Modulate activity of Nuclear Retinoid receptors; regulating cell differentiation and cell cycle processes and cellular signaling processes regulated by thyroid hormone, vitamin D, all-trans retinoic acid; 2-[6-(3-Adamantan-1-yl-4-methoxyphenyl)-naphthalen-2-yl]-3-hydroxy-cyclopent-2-enone |
| 12/23/2008 | US7468457 Skin disorders; antiproliferative agents; metabolism disorders; obesity; antihistamines; antidiabetic agents |
| 12/23/2008 | US7468449 Phenyl-furan compounds as vitamin D receptor modulators |